StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)

Close on Nov 17, 2026Market cap $1.78BP/E –Yield –

Agios Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Agios Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 92.0%. For fiscal 2025 it was 88.3%, against 88.6% the year before. The highest annual figure on record is 100.0% in fiscal 2016.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202588.3%−0.3
FY2024Dec 31, 202488.6%−0.7
FY2023Dec 31, 202389.3%+1.2
FY2022Dec 31, 202288.0%−10.8
FY2019Dec 31, 201998.9%+0.4
FY2018Dec 31, 201898.5%−1.5
FY2017Dec 31, 2017100.0%+0.0
FY2016Dec 31, 2016100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202693.3%+7.0
Q1 FY2026Mar 31, 202693.6%+6.1
Q4 FY2025Dec 31, 202590.6%+2.3
Q3 FY2025Sep 30, 202587.0%−4.3
Q2 FY2025Jun 30, 202586.3%+3.7
Q1 FY2025Mar 31, 202587.6%−4.8
Q4 FY2024Dec 31, 202488.3%−3.5
Q3 FY2024Sep 30, 202491.3%−0.2
Q2 FY2024Jun 30, 202482.6%−0.8
Q1 FY2024Mar 31, 202492.3%+2.2
Q4 FY2023Dec 31, 202391.7%+1.3
Q3 FY2023Sep 30, 202391.4%+6.1
Q2 FY2023Jun 30, 202383.5%−8.7
Q1 FY2023Mar 31, 202390.1%+30.9
Q4 FY2022Dec 31, 202290.4%−7.4
Q3 FY2022Sep 30, 202285.3%−12.9
Q2 FY2022Jun 30, 202292.2%−6.0
Q1 FY2022Mar 31, 202259.3%−40.1
Q4 FY2020Dec 31, 202097.8%−1.4
Q3 FY2020Sep 30, 202098.2%−0.3
Q2 FY2020Jun 30, 202098.2%−0.7
Q1 FY2020Mar 31, 202099.4%+0.5
Q4 FY2019Dec 31, 201999.2%+1.5
Q3 FY2019Sep 30, 201998.5%+3.1
Q2 FY2019Jun 30, 201998.8%−1.2
Q1 FY2019Mar 31, 201998.9%−1.1
Q4 FY2018Dec 31, 201897.7%−2.3
Q3 FY2018Sep 30, 201895.4%−4.6
Q2 FY2018Jun 30, 2018100.0%–
Q1 FY2018Mar 31, 2018100.0%–
Q4 FY2017Dec 31, 2017100.0%–
Q3 FY2017Sep 30, 2017100.0%–

More Agios Pharmaceuticals figures

See a number that looks wrong?